Altamira Therapeutics Completes Interim Sample Size Analysis of COVAMID Trial with Bentrio in Acute COVID-19
HAMILTON, BERMUDA , Aug. 01, 2022 (GLOBE NEWSWIRE) -- Enrollment to be continued to 160 subjects, adding 24 to ensure...
Clinical Trial
SCYNEXIS Announces U.S. Food and Drug Administration Acceptance and Priority Review of the Supplemental New Drug Application for BREXAFEMME® (ibrexafungerp tablets) for Prevention of Recurrent Vaginal Yeast Infections
Submission has been granted priority review and given a target regulatory decision date of November 30, 2022.If approved for this...
Qualigen Therapeutics Reports Positive QN-247 Readout in Triple Negative Breast Cancer in Vivo Model
CARLSBAD, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on...
Catalyst Biosciences Publishes New Investor Presentation
Provides Details on Current Board’s Cash Distribution Plan and Efforts to Maximize the Amount of Cash Available for Distribution Company...
Albireo to Report Q2 2022 Financial Results on August 15, 2022
Conference call and webcast to be held at 4:30 pm ETBOSTON, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc....
Altamira Therapeutics’ Delivery Platform with siRNA Shown to be Effective Treatment for Osteoarthritis as Published in Peer-Reviewed Journal
•Independent peer-reviewed study confirms high potential for OligoPhoreTM delivery platform in RNA-based treatments for osteoarthritis •Knock down of JMJD3 gene...
Sientra to Report Second Quarter 2022 Financial Results on August 11, 2022
SANTA BARBARA, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company...
Veru to Report Fiscal 2022 Third Quarter Financial Results, Host Conference Call on August 11th
MIAMI, July 28, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for...
Sunshine Biopharma Increases Support for Anti-Coronavirus Collaborative Research With the University of Arizona
MONTREAL, July 28, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM” and SBFMW) (the “Company” or “Sunshine Biopharma”), a...
Caladrius Biosciences to Host Second Quarter 2022 Financial Results Conference Call on Thursday, August 4, 2022, at 4:30 p.m. Eastern Time
BASKING RIDGE, N.J., July 28, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage...
Vallon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
PHILADELPHIA, PA, July 28, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical...
GigaGen Publishes Research Showcasing First-Ever Clinical GMP Manufacturing and IND-Enabling Studies for its New Class of Drugs, Recombinant Polyclonal Antibodies
SOUTH SAN FRANCISCO, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for...
Akari Therapeutics Announces Positive Results from Recent Pre-Clinical Studies of Investigational PASylated® Nomacopan That Support the Potential to Advance Research Toward IND/IMPD for Clinical Trials in Geographic Atrophy
Positive results from recent pre-clinical studies support the potential of long-acting PASylated nomacopan to advance toward IND/IMPD for clinical trials...
Rhythm Pharmaceuticals to Report Second Quarter 2022 Financial Results on Tuesday, August 2, 2022
BOSTON, July 28, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the...
Biofrontera Inc. Announces Exercise of Existing Warrants and Issuance of Warrants in Private Placement
WOBURN, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of...
180 Life Sciences Announces That the University of Oxford Has Been Awarded a Grant From the National Institute for Health and Care Research in the U.K. to Conduct a Clinical Trial in Post Operative Delirium/Cognitive Deficit in a Jointly Funded Program With 180 Life Sciences Corp.
PALO ALTO, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the...
Palisade Bio Announces First Patient Screened in Phase 3 Study Evaluating LB1148 for Postoperative Return of Bowel Function
CARLSBAD, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for...
Medicenna Announces New Clinical Data Providing Preliminary Evidence of MDNA11’s Single Agent Anti-Cancer Activity in the Phase 1/2 ABILITY Study
-- Tumor control was achieved in four of ten evaluable patients with advanced solid tumors unresponsive to other treatments enrolled...
INmune Bio, Inc. to Report Second Quarter 2022 Financial Results and Provide a Corporate Update on Wednesday, August 3
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, July 27, 2022...
Eyenovia Announces Appointment of Ophthalmic Industry Veteran Michael Rowe as Chief Executive Officer and Board Member
Appointment of Mr. Rowe, Eyenovia’s current Chief Operating Officer, maintains continuity while bringing significant ophthalmic industry, operations and commercialization expertise...